TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Geometric mean length of healthy nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to dietary Na intake (≤2,500 mg/d)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Na levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary Na intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of inflammation and staining of gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: malunion and non-union rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: satisfaction with treatment outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perinatal mortality due to fetal hypoxia
Endpoint domain: Mortality/survival
Primary endpoint: Rate of surgical intervention for suspected fetal distress
Endpoint domain: Adverse events/effects
Primary endpoint: Anticoagulation control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warfarin knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Supplement adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rehabilitation session adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: myosin fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mitochondrial muscle protein fractional synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MASI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: fear of movement/(re)injury
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wavelet thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Energy component of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NMD (Nitroglycerin-Mediated Dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Normalization of PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Early reactivation requiring urgent intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial infarction during reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in irritability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative doses of clonazepam and zuclopenthixol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful tracheal intubation on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postural response latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural response burst duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural response burst magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TVF
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of ST
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total and delayed recall from the Hopkins Verbal Learning Test‐Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop Color‐Word score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation patterns during fMRI tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No longer met criteria for primary diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Did not meet criteria for any anxiety disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: Did not meet criteria for any DSM-IV disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Mental health outcomes
Primary endpoint: major postoperative complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: overall postoperative mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative implant survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Activity of Daily Life (ADL) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural Motor Function Deficits (NFDS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of necrotising enterocolitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of shivering (Grades 1-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depersonalisation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Personal accomplishment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: in-stent mean neointimal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target vessel revascularizations (TVRs)
Endpoint domain: Adverse events/effects
Primary endpoint: myocardial infarctions (MIs)
Endpoint domain: Adverse events/effects
Primary endpoint: functional connectivity in the executive control network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: functional connectivity in the auditory/sensorimotor network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Investigator Global Assessment (IGA) score 0/1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain/discomfort rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of T2DM
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of adherence behaviour measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PINI values in patients with pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of SaO2 < 90% episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: performance accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS values on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total analgesic requirement in the first 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of analgesia in the first 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum LDL cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum HDL cholesterol increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean number of translocations per cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS20 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PWD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of postpartum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: annualized change in percent wall volume (%WV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Perceived risk for developing common diseases
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: relapse to heavy drinking
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in venous scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: u-PA antigen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma insulin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Smoking status at end-of-pregnancy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver reproducibility of ultrasound measurements of fetal biometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver reproducibility of ultrasound measurements of fetal biometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CBS 844ins68 and MS A2756G mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High residual volume fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in physical health dimension of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in social relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Global rating of change scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Good cardiometabolic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observer-rated visual analogue scale for pain during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acquisition and assimilation of cognitive knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the teaching method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fall asthma exacerbation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADL score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Circulating levels of endothelin (ET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating levels of calcitonin gene-related peptide (CGRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating levels of atrial natriuretic peptide (ANP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma IL-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Program use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of nocturnal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P300 component amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding or spotting duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary isoprostane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ab-oxLDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 14-day case fatality rate
Endpoint domain: Mortality/survival
Primary endpoint: complete antiemetic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea (posttreatment visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to the first EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level
Endpoint domain: Adverse events/effects
Primary endpoint: Serotype-specific IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 11β‐HSD1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 5α‐reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Caloric intake change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of multiple dimensions of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast fibrosis
Endpoint domain: Adverse events/effects
Primary endpoint: contralateral breast cancer
Endpoint domain: Adverse events/effects
Primary endpoint: distant metastases
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular (LV) diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: S aureus colonization and food allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distant recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Post-void residual (PVR) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: diaphragmatic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diseases requiring inpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean change in DSM-IV Total ADHD Symptoms subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hoarding symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase II pulmonary VO2 response time constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perform functional tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of blocks successfully grasped and released
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in detecting malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity in detecting malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in detecting malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall score of the WOMAC questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score of the WOMAC questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stiffness score of the WOMAC questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity score of the WOMAC questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma TMAO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median visual analogue pain score on day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median cosmetic score at 3 months after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease of TQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myocardial perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thickness of the oesophageal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of oesophageal damage associated with sclerotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual-Motor Integration (VMI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Perception (VP) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Coordination (MC) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the glucose curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disposition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolite changes in non-lesioned M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response associated with baseline lesioned M1 metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gynaecomastia development
Endpoint domain: Adverse events/effects
Primary endpoint: Breast pain occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Improved overall response rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: proptosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of positive cultures
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of (pre-)malignancy in new subsolid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resolution of subsolid nodules with follow-up screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Rate (FR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sternal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with decision making
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful withdrawal of inhaled corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of wheezing
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in VISA-P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCa mortality
Endpoint domain: Mortality/survival
Primary endpoint: total rate of hospitalizations plus deaths
Endpoint domain: Mortality/survival
Primary endpoint: incidence of orthostatic hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: VAS score at rest and during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute chemoradiation toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: long-term chemoradiation toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: daytime hypoglycaemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative doses of morphine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EQ‐5D‐5L index value
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in pliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in median VSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: symptomatic healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PCR-corrected PP cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the plasma concentration‐time curve (AUC0‐∞) of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 3 and 5-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Clinical acute graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biopsy-proven acute graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes